![Pinterest](https://pinterest.com/pin/create/button/?url=https://bollspel.com/finding-the-ultimate-antithrombotic-therapy-after-tmvr/&media=https://bollspel.com/wp-content/uploads/2024/01/17028-finding-the-ultimate-antithrombotic-therapy-after-tmvr.jpg&description="Discover the most effective antithrombotic therapy options for patients undergoing transcatheter mitral valve replacement (TMVR) in this comprehensive guide. Learn how to find the ultimate treatment for preventing blood clots and strokes post-procedure."){kind=link}
TOPLINE:
Patients undergoing transcatheter mitral valve replacement (TMVR) who receive direct oral anticoagulants (DOACs) have fewer bleeding and thrombotic events and shorter hospital stays than those taking vitamin K antagonists (VKAs), a new observational study showed.
METHODOLOGY:
- The study included 156 relatively frail and comorbid patients, mean age 65 years and 66% women, who underwent TMVR between 2011 and 2023 and received either DOACs or VKAs, with heparin bridging at discharge. (Until 2019, most patients were prescribed VKAs; since then, DOACs have become the preferred choice.)
- Patients without an indication for lifelong anticoagulation discontinued anticoagulants after 3-6 months if imaging tests (transesophageal echocardiography [TEE] and/or CT ) confirmed the absence of valve thrombosis and were prescribed lifelong aspirin therapy.
- The primary outcome was any bleeding; secondary outcomes included thrombotic complications (valve thrombosis or stroke), death, major vascular complications, and length of stay.
- Patients were followed regularly after the procedure through clinic visits during which transthoracic echocardiography and contrast CT were done unless contraindicated (90% also had at least one cardiac CT, and 79% had at least one TEE during follow-up).
- Variables in the final models for thrombotic events and length of stay included age, sex, and aspirin therapy.
TAKEAWAY:
- During a median follow-up of 4.7 months, bleeding events were more common in the VKA group than in the DOAC group (35% vs 9%; P = .02), a difference that was also statistically significant for major bleeding (14% vs 0%; P = .01), and there was a trend suggesting a higher occurrence of minor bleeding in the VKA group (23% vs 9%; P = .09).
- A landmark Kaplan-Meier analysis showed a significant difference in bleeding events between DOACs and VKAs within the first month (adjusted hazard ratio, 0.20; 95% CI, 0.06-0.71; P = .01), but not beyond 30 days (P = .20), which emphasizes the critical period immediately following the procedure as especially risk-prone because of heparin bridging (used with VKA), said the authors.
- There were no significant differences in the risk for thrombotic events (P = .24), including valve thrombosis (P = .12) and stroke (P = 1.00) between groups, and there were no deaths in either group.
- The length of hospital stay was shorter in the DOAC group (4.50 days vs 8.00 days; P < .001), and this difference remained significant after adjustment (P = .002).
IN PRACTICE:
Given the association between bleeding and adverse events after TMVR, “all efforts should be made to minimize the risk of bleeding events in these patients,” the authors wrote.
In an accompanying editorial, Jurriën M. ten Berg, MD, PhD, Departments of Cardiology, St. Antonius Hospital, Nieuwegein, and Maastricht University Center and Cardiovascular Research Institute,